Nuclear Imaging

Physicians will need to use a CMS-certified appropriate use criteria (AUC) clinical decision support software that documents the appropriateness of an imaging order to receive full reimbursement for Medicare patients starting Jan. 1, 2018.

Feature | Cardiac Imaging | April 18, 2017 | Dave Fornell

As part of U.S. healthcare reform efforts, starting Jan. 1, 2018, physicians will be required to document they are...

University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017

April 13, 2017 — The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA...

IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers | April 11, 2017

April 11, 2017 — IBA Molecular announced that it has merged with previous acquisition Mallinckrodt...

GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers | April 05, 2017

April 5, 2017 — GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization...

Northwestern Memorial Hospital, MR-PET scanner, first in Illinois, Siemens Biograph mMR
News | PET-MRI | March 31, 2017

March 31, 2017 — Northwestern Memorial Hospital is now home to the Chicago area's first combined magnetic resonance...

PET imaging, atherosclerotic plaque, inflammation, Ga-68-pentixafor, Technishe Universitat Munchen, Germany

Note the high uptake of Ga-68-pentixafor on multi-planar reconstructions in the organs expressing CXCR4 such as the spleen (red arrows) and adrenal glands (yellow arrows), which was nearly completely blocked by the pre-injection of AMD 3100, a potent CXCR4 inhibitor. Strong accumulation of Ga-68-pentixafor was also found in the kidneys (asterisks) reflecting the renal clearance of the tracer. In addition, high, focal activities were detected in the abdominal aorta (red arrowheads) and right carotid artery (orange arrowheads) of atherosclerotic rabbits, whereas no significant signal could be detected in the non-injured left carotid artery (white arrowheads) of atherosclerotic and control rabbits, as well as in the abdominal aorta and right carotid artery of control rabbits. Furthermore, focal activities detected with PET in atherosclerotic plaques of the abdominal aorta and the right carotid artery decreased significantly when the same rabbit was re-imaged after blocking CXCR4 receptors. Image courtesy of Fabien Hyafil, M.D., Ph.D., Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

News | PET Imaging | March 03, 2017

March 3, 2017 — In the featured article of the March 2017 issue of...

Nuclear cardiology, nuclear imaging, radiotracer production, automated radiosynthesis module, myocardial perfusion imaging
Feature | Radiopharmaceuticals and Tracers | March 01, 2017 | Anamika Kumari

Huge portions of the globally produced radiotracers find their origin within geographically centralized, commercial...

GE Healthcare, Rapiscan stress imaging agent, North America, Rapidscan Pharma Solutions Inc.
News | Pharmaceuticals | February 07, 2017

February 7, 2017 — GE Healthcare’s Life Sciences business announced in January that it acquired Rapidscan Pharma...

IBA Molecular, acquisition, Mallinckrodt Nuclear Imaging, nuclear imaging
News | Nuclear Imaging | January 30, 2017

January 30, 2017 — IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging,...

stress, brain activity, cardiovascular risk, PET-CT, MGH, ISSMS, The Lancet study
News | Cardiac Diagnostics | January 18, 2017

January 18, 2017 — A study led by Massachusetts General Hospital (MGH) and Icahn School of Medicine at Mount Sinai (...

News | Radiopharmaceuticals and Tracers | January 17, 2017

January 17, 2017 — NorthStar Medical Technologies LLC has received additional matching funds from the U.S....

Medrad Intego PET Infusion System, recall
News | Nuclear Imaging | January 12, 2017

January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source...

Nuclear cardiology, dose reduction, myocardial perfusion imaging
News | Nuclear Imaging | January 05, 2017

January 5, 2017 — Working in concert, the American Society of Nuclear Cardiology (ASNC), the Intersocietal...

SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals
News | Radiopharmaceuticals and Tracers | December 28, 2016

December 28, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has developed United States...

PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia.

News | Nuclear Imaging | December 06, 2016

December 6, 2016 — Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac...

Overlay Init